Vallon Pharmaceuticals VLON

$ 0.43 -6.47%

Quarterly report 2024-Q3
added 11-14-2024

Vallon Pharmaceuticals Balance Sheet 2011-2024 | VLON

Annual Balance Sheet Vallon Pharmaceuticals

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-48 K	-3.48 M	-613 K	-	-	-	-	-	-	-
Long Term Debt	-	14 K	-	14 K	-	-	-	-	-	-	-	-	-
Long Term Debt Current	14 K	57 K	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	184 K	254 K	-	-	-	-	-	-	-	-
Total Current Liabilities	2.7 M	1.99 M	2.44 M	-	-	-	-	-	-	-	-	-	-
Total Liabilities	2.7 M	2.01 M	2.52 M	2.41 M	1.06 M	486 K	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-31.5 M	-18.5 M	-21.9 M	-12.6 M	-7.78 M	-4.31 M	-	-	-	-	-	-	-
Total Assets	2.96 M	383 K	8.34 M	955 K	4.28 M	639 K	-	-	-	-	-	-	-
Cash and Cash Equivalents	1.81 M	9 K	3.7 M	109 K	-	-	-	-	-	-	-	-	-
Book Value	259 K	-1.62 M	5.82 M	-1.45 M	3.21 M	153 K	-	-	-	-	-	-	-
Total Shareholders Equity	259 K	-1.62 M	5.82 M	-1.45 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Vallon Pharmaceuticals

	2024-Q3	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	84 K	-	-	-	-	14 K	-	-	-	72 K	-	-	146 K	170 K	-	-	170 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	1.8 M	2.7 M	2.18 M	1.6 M	2.07 M	2.01 M	2.11 M	-	2.58 M	2.52 M	1.41 M	1.79 M	2.57 M	2.41 M	2.41 M	2.41 M	2.41 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-37.8 M	-31.5 M	-29.5 M	-27.4 M	-31.3 M	-18.5 M	-27.3 M	-	-24.5 M	-21.9 M	-18.8 M	-17.5 M	-15.2 M	-12.6 M	-12.6 M	-12.6 M	-12.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	5.46 M	2.96 M	4.4 M	5.64 M	2.1 M	383 K	5.57 M	-	5.94 M	8.34 M	10.1 M	11.6 M	14.6 M	955 K	955 K	955 K	955 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	4.75 M	1.81 M	3.49 M	4.8 M	1.66 M	9 K	104 K	9 K	2.54 M	3.7 M	5.88 M	10.5 M	13 M	109 K	109 K	109 K	109 K	3.82 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	3.66 M	259 K	2.23 M	4.04 M	31 K	-1.62 M	3.46 M	-	3.36 M	5.82 M	8.73 M	9.85 M	12 M	-1.45 M	-1.45 M	-1.45 M	-1.45 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	3.66 M	259 K	2.23 M	4.04 M	-3.23 M	-1.62 M	-5.71 M	-5.44 M	-5.15 M	5.82 M	8.73 M	9.85 M	12 M	-1.45 M	-1.45 M	-1.45 M	-1.45 M	3.21 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency